Abstract
Background: Angiogenesis inhibitors (AIs) have become established as an effective cancer treatment. Whereas their interactions with antineoplastic drugs have extensively been investigated, little is known of the effect of their co-administration with nutraceuticals/dietary supplements (N/DSs), which are often self-prescribed. N/DSs comprise a wide range of products such as herbs, nutrients, vitamins, minerals, and probiotics. Assessment of their interactions with cancer drugs, particularly AIs, is hampered by the difficulty of gauging the amount of active substances patients actually take. Moreover, there is no agreement on which approach should be used to determine which N/DSs are most likely to influence AI treatment efficacy. We present a comprehensive review of the metabolic routes of the major AIs and their possible interactions with N/DSs. Methods: The PubMed and Cochrane databases were searched for papers describing the metabolic routes of the main AIs and N/DSs. Results: Data from the 133 studies thus identified were used to compile a diagnostic table reporting known and expected AI-N/DS interactions based on their metabolization pathways. AIs and N/DSs sharing the cytochrome P450 pathway are at risk of negative interactions. Conclusions: Recent advances in pharmacogenetics offer exceptional opportunities to identify prognostic and predictive markers to enhance the efficacy of individualized AI treatments. The table provides a guide to genotyping patients who are due to receive AIs and is a promising tool to prevent occult AI-N/DS interactions in poor metabolizers. N/DS use by cancer patients receiving AIs is a topical problem requiring urgent attention from the scientific community.
Highlights
The growth of bulky tumors and metastatic masses depends on the formation of new blood vessels, i.e., angiogenesis [1]
Data from 22 of the 2437 studies identified were used to compile a diagnostic table reporting known and expected Angiogenesis inhibitors (AIs)-nutraceuticals/dietary supplements (N/DSs) interactions based on their metabolization pathways
AIs and N/DSs sharing the cytochrome P450 pathway are at risk of negative interactions
Summary
The growth of bulky tumors and metastatic masses depends on the formation of new blood vessels, i.e., angiogenesis [1]. Cells 2019, 8, 522 capillaries from existing vessels) and non-sprouting processes (EC multiplication in vessel walls) [3] The latter mechanism is closely dependent on vascular endothelial growth factor (VEGF), a vascular permeability factor [4,5,6]. Angiogenesis inhibitors (AIs) have become established as an effective cancer treatment Whereas their interactions with antineoplastic drugs have extensively been investigated, little is known of the effect of their co-administration with nutraceuticals/dietary supplements (N/DSs), which are often self-prescribed. N/DSs comprise a wide range of products such as herbs, nutrients, vitamins, minerals, and probiotics Assessment of their interactions with cancer drugs, AIs, is hampered by the difficulty of gauging the amount of active substances patients take. AIs and N/DSs sharing the cytochrome P450 pathway are at risk of negative interactions
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
